Kalaris Therapeutics, Inc. 8-K

What Happened
Kalaris Therapeutics, Inc. (KLRS) filed an 8‑K reporting that Chief Financial Officer Matthew Gall notified the company on April 8, 2026 that he will resign as CFO effective April 14, 2026. As a result, Brett Hagen, the company’s Chief Accounting Officer and principal accounting officer, will also serve as the company’s principal financial officer effective on the separation date.

Key Details

• Resignation notice given April 8, 2026; effective separation date April 14, 2026.
• Brett Hagen (age 53) has served as Chief Accounting Officer since January 2019 and will take on the principal financial officer role immediately.
• Mr. Hagen’s prior roles include senior director finance and accounting at Eloxx Pharmaceuticals, VP finance/controller at Proteostasis Therapeutics, and controller at BIND Therapeutics; he holds degrees from the University of Minnesota, Wright State University (accounting) and Suffolk University (finance).
• The company disclosed no family relationships or related‑party transactions for Mr. Hagen and stated there were no changes to his compensatory plans in connection with this appointment.

Why It Matters
A CFO resignation and immediate internal appointment of the principal financial officer affects who oversees financial reporting and controls. For investors, this signals continuity in finance leadership (internal promotion) and no immediate change in compensation or disclosed related‑party issues. Watch future filings (quarterly/annual reports) for any further leadership updates or disclosures about the transition and its impact on financial reporting.